GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (SHSE:603127) » Definitions » Shares Outstanding (EOP)

Joinn Laboratories (China) Co (SHSE:603127) Shares Outstanding (EOP) : 750 Mil (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Joinn Laboratories (China) Co Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Joinn Laboratories (China) Co's shares outstanding for the quarter that ended in Mar. 2024 was 750 Mil.

Joinn Laboratories (China) Co's quarterly shares outstanding stayed the same from Dec. 2023 (750 Mil) to Mar. 2024 (750 Mil).

Joinn Laboratories (China) Co's annual shares outstanding declined from Dec. 2022 (750 Mil) to Dec. 2023 (750 Mil). It means Joinn Laboratories (China) Co bought back shares from Dec. 2022 to Dec. 2023 .


Joinn Laboratories (China) Co Shares Outstanding (EOP) Historical Data

The historical data trend for Joinn Laboratories (China) Co's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Joinn Laboratories (China) Co Shares Outstanding (EOP) Chart

Joinn Laboratories (China) Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 621.25 624.14 747.24 749.95 749.89

Joinn Laboratories (China) Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 749.95 715.95 749.89 749.89 749.89

Competitive Comparison of Joinn Laboratories (China) Co's Shares Outstanding (EOP)

For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Joinn Laboratories (China) Co's Shares Outstanding (EOP) Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Joinn Laboratories (China) Co's Shares Outstanding (EOP) falls into.



Joinn Laboratories (China) Co Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Joinn Laboratories (China) Co  (SHSE:603127) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Joinn Laboratories (China) Co Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Joinn Laboratories (China) Co (SHSE:603127) Business Description

Traded in Other Exchanges
Address
A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Executives
Yao Da Lin Director
Sun Yun Xia Director
Zuo Cong Lin Director
Gao Da Peng Director
Li Ye Supervisors
Gu Xiao Lei Director
Feng Yu Xia Director
Gu Jing Liang senior management
Yu Ai Shui senior management
Yin Li Li Supervisors
Sun Hui Ye Supervisors
Gu Mei Fang Director

Joinn Laboratories (China) Co (SHSE:603127) Headlines

No Headlines